News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
